Results 221 to 230 of about 11,744,847 (379)

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

From Moral Fixed Points to Epistemic Fixed Points

open access: yes, 2018
In a recent paper Terence Cuneo and Russ Shafer-Landau argue that there are moral conceptual truths that are substantive in content, what they called “moral fixed points.” I argue that insofar as we have some reason to postulate moral fixed points, we have equal reason to postulate epistemic fixed points (e.g. the factivity condition).
openaire   +3 more sources

Hardware Implementation of a Fixed-Point Decoder for Low-Density Lattice Codes. [PDF]

open access: yesJ Signal Process Syst, 2022
Srivastava R, Gaudet VC, Mitran P.
europepmc   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

open access: yesMolecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Research on Subpixel Algorithm of Fixed-Point Tool Path Measurement. [PDF]

open access: yesComput Intell Neurosci, 2021
Zhang X, Guo Z, Liu X, Zhang L.
europepmc   +1 more source

Clinical significance of stratifying prostate cancer patients through specific circulating genes

open access: yesMolecular Oncology, EarlyView.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy